


I hereby Certify that this Correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to:
Commissioner for Patents, Alexandria,
VA 22313, on 16 September 2003.

M. Bud Nelson
Name 
Signature 
Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mary K. Delmedico & John Dwyer

Application No.

Examiner:

Filed: 16 September 2003

Art Unit

For: HIV-derived HR1 peptides modified to form stable trimers,
and their use in therapy to inhibit transmission of Human
Immunodeficiency Virus

Commissioner for Patents
Alexandria, VA

Docket No. TRM-001

INFORMATION DISCLOSURE STATEMENT
37 CFR 1.56 and 1.97

Applicants wish to make of record the following reference under the provisions of 37 CFR 1.56 and 1.97 **and** to provide a copy of relevant background with respect to the application. The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application, or is to be considered material to patentability as defined in 37 CFR §1.56(b).
Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove any document as a cited reference against the claims of the present invention.

References Cited

Please see attached Form PTO-1449 for list of publications, legible copies of all publication listed are enclosed.

Statement of Relevancy

Non Patent Literature Documents

Cites 1,2, 7, 8, and 9 generally relate to HR1 peptides.

Cites 3, 4, 5, 6, 9, and 10 generally relate to gp41 structure.

Patent Documents

Cites 11,12, 16 & 18 generally relate to HR1 peptides.

Cites 13, 14, 17 & 19 generally relate to modifications of HR peptides.

Cite 15 generally relates to gp41 structures.

Respectfully submitted,



M. Bud Nelson
Reg. No. 35,300
Attorney for the Applicants

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<i>Compleat if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	
		Filing Date	16 Sept. 2003
		First Named Inventor	Delmedico, May Kay
		Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	
		TRM-001	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

of 2

Complet if Known

Digitized by srujanika@gmail.com

cation Number _____

16

6 Sept. 2003

or Delmedico, May Kay

Concord, May 1st,

Digitized by srujanika@gmail.com

10. The following table summarizes the results of the study.

Number TBM-001

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Compl te if Known	
		Application Number	
		Filing Date	16 Sept. 2003
		First Named Inventor	Delmedico, Mary Kay
		Art Unit	
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	TRM-001

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	1.	WILD et al.; "A synthetic peptide inhibitor of human immunodeficiency virus replication...."; Nov. 1992; 10537-10541; vol 89; Proc. Natl. Acad. Sci. USA		T ²
	2.	WILD et al.; " A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell-Cell Fusion"; Nov. 11, 1993; 1051-1053; vol 9; Mary Ann Liebert, Inc., Publishers		
	3.	CHAN et al.; "Core Structure of gp41 from the HIV Envelope Glycoprotein"; April 18, 1997; 263-273; vol 89; Cell Press		
	4.	SHU et al.; "Trimerization Specificity in HIV-1 gp41: Analysis with a GCN4 Leucine Zipper Model"; April 1999; 5378-5385; vol 38; Biochemistry		
	5.	ECKERT et al.; "Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket"; Oct. 1, 1999; 103-115; vol 99; Cell Press		
	6.	ROOT et al.; " Protein Design of an HIV-1 Entry Inhibitor"; Feb. 1, 2001; 884-888; vol 291; SCIENCE		
	7.	LOUIS et al.; " Design and Properties of Nccg-gp41, a Chimeric gp41 Molecule with Nanomolar ..."; Aug. 3, 2001; 29485-29489; vol 276; no. 31; Journal of Biological Chemistry		
	8.	BEWLEY et al.; " Design of a Novel Peptide Inhibitor of HIV Fusion....."; April 19, 2002; 14238-14245; vol 277; no. 16; Journal of Biological Chemistry		
	9.	LAWLESS et al.; " HIV-1 Membrane Fusion Mechanism: Structural Studies of the Interactions...."; 1996; 13697-13708; vol 35, no. 42; Biochemistry		
	10	HARBURY et al. "A Switch Between Two-, Three- and Four-Stranded Coiled Coils....."; 1993; 1401-1407; vol. 262, Science.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.